A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT07783802
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT07783802
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Japan, Puerto Rico
- Registry status
- Recruiting
Technical summary
Registry record NCT07783802. Randomized; double masking; primary purpose treatment. Start 2026-08-27 (actual); primary completion 2027-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Acronym
- CLARITY-CRP
- Condition
- Atherosclerosis
- Condition
- Cardiovascular Disease
- Condition
- Obesity
- Condition
- Hypertension
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Renal Insufficiency, Chronic
- Intervention (Drug)
- Clazakizumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07783802- Content hash
57f8eaa224e72767b4f0a3c2bd10277df7ef06451065bc7848884195ff6eeca3